Charis L Himeda
Overview
Explore the profile of Charis L Himeda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
606
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Himeda C, Jones T, Jones P
Hum Gene Ther
. 2024 Jul;
35(15-16):543-554.
PMID: 38970421
Adeno-associated virus-mediated gene therapies for certain muscle disorders require regulatory cassettes that provide high-level, striated muscle-specific activity. However, cardiotoxicity has emerged as a serious concern in clinical trials for Duchenne...
2.
Himeda C, Jones P
J Pers Med
. 2022 Jun;
12(6).
PMID: 35743650
Facioscapulohumeral muscular dystrophy (FSHD) is arguably one of the most challenging genetic diseases to understand and treat. The disease is caused by epigenetic dysregulation of a macrosatellite repeat, either by...
3.
Himeda C, Jones T, Jones P
Mol Ther Methods Clin Dev
. 2021 Jan;
20:298-311.
PMID: 33511244
Facioscapulohumeral muscular dystrophy (FSHD) is caused by incomplete silencing of the disease locus, leading to pathogenic misexpression of in skeletal muscle. Previously, we showed that CRISPR inhibition could successfully target...
4.
Himeda C, Jones P
Dev Cell
. 2019 Sep;
50(5):525-526.
PMID: 31505171
In this issue of Developmental Cell, Chew et al. (2019) show that the pioneer factor DUX4 is misexpressed in tumors, where it suppresses anti-tumor immune activity. Their findings provide a...
5.
Himeda C, Jones P
Annu Rev Genomics Hum Genet
. 2019 Apr;
20:265-291.
PMID: 31018108
Facioscapulohumeral muscular dystrophy (FSHD), a progressive myopathy that afflicts individuals of all ages, provides a powerful model of the complex interplay between genetic and epigenetic mechanisms of chromatin regulation. FSHD...
6.
Himeda C, Jones T, Virbasius C, Zhu L, Green M, Jones P
Mol Ther
. 2018 May;
26(7):1797-1807.
PMID: 29759937
Facioscapulohumeral muscular dystrophy (FSHD) is caused by epigenetic de-repression of the disease locus, leading to pathogenic misexpression of the DUX4 gene in skeletal muscle. While the factors and pathways involved...
7.
Jones T, Himeda C, Perez D, Jones P
Neuromuscul Disord
. 2017 Feb;
27(3):221-238.
PMID: 28161093
Facioscapulohumeral muscular dystrophy (FSHD) is associated with aberrant epigenetic regulation of the chromosome 4q35 D4Z4 macrosatellite repeat. The resulting DNA hypomethylation and relaxation of epigenetic repression leads to increased expression...
8.
Himeda C, Jones T, Jones P
Trends Pharmacol Sci
. 2016 Feb;
37(4):249-251.
PMID: 26917062
Versatility of CRISPR/Cas9-based platforms makes them promising tools for the correction of diverse genetic/epigenetic disorders. Here we contrast the use of these genome editing tools in two myopathies with very...
9.
Himeda C, Jones T, Jones P
Mol Ther
. 2015 Nov;
24(3):527-35.
PMID: 26527377
Facioscapulohumeral muscular dystrophy (FSHD) is one of the most prevalent myopathies, affecting males and females of all ages. Both forms of the disease are linked by epigenetic derepression of the...
10.
Jones T, King O, Himeda C, Homma S, Chen J, Beermann M, et al.
Clin Epigenetics
. 2015 Apr;
7:37.
PMID: 25904990
Background: Both forms of facioscapulohumeral muscular dystrophy (FSHD) are associated with aberrant epigenetic regulation of the chromosome 4q35 D4Z4 macrosatellite. Chromatin changes due to large deletions of heterochromatin (FSHD1) or...